Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Catalyst Pharmaceuticals (CPRX) Equity Ratio: 2010-2025

Historic Equity Ratio for Catalyst Pharmaceuticals (CPRX) over the last 13 years, with Sep 2025 value amounting to 0.88.

  • Catalyst Pharmaceuticals' Equity Ratio rose 2.21% to 0.88 in Q3 2025 from the same period last year, while for Sep 2025 it was 0.88, marking a year-over-year increase of 2.21%. This contributed to the annual value of 0.85 for FY2024, which is 3.58% up from last year.
  • According to the latest figures from Q3 2025, Catalyst Pharmaceuticals' Equity Ratio is 0.88, which was down 0.64% from 0.88 recorded in Q2 2025.
  • Over the past 5 years, Catalyst Pharmaceuticals' Equity Ratio peaked at 0.91 during Q1 2021, and registered a low of 0.80 during Q4 2022.
  • Over the past 3 years, Catalyst Pharmaceuticals' median Equity Ratio value was 0.86 (recorded in 2024), while the average stood at 0.85.
  • Its Equity Ratio has fluctuated over the past 5 years, first grew by 7.13% in 2021, then decreased by 8.90% in 2022.
  • Catalyst Pharmaceuticals' Equity Ratio (Quarterly) stood at 0.87 in 2021, then dropped by 8.05% to 0.80 in 2022, then rose by 3.16% to 0.83 in 2023, then grew by 3.58% to 0.85 in 2024, then climbed by 2.21% to 0.88 in 2025.
  • Its Equity Ratio stands at 0.88 for Q3 2025, versus 0.88 for Q2 2025 and 0.87 for Q1 2025.